Long-term safety of Ixekizumab (IXE) - 26 RCTs (22k PYs) in PSO, PsA, AS & nr-axSpA - nasopharyngitis most common AE; AEs did not incr over time - D/C from AE 3-5/100Pys - ISRs: 5.9-11.6/100PYs - Candida 1.2-2/100PYs - IBD: 0.1 PsO - 0.8/100PY for axSpA https://t.co/nOoCE3VOxD https://t.co/F4gP1yR1Je